Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
NCT01129648 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87
Last updated 2012-01-23
Summary
To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
Conditions
Interventions
- DRUG
-
Administered daily for 21 days
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
BCX4208
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
BCX4208
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
BCX4208
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
Allopurinol
Administered daily for 21 days.
- DRUG
-
BCX4208
Adminstered daily for 21 days
Sponsors & Collaborators
-
BioCryst Pharmaceuticals
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 69 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2010-11-30
- Completion
- 2010-11-30
Countries
- United States
Study Locations
More Related Trials
-
Allopurinol Combination Study
NCT01001338 ·Status: COMPLETED ·Phase: PHASE2
-
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
NCT00829829 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
NCT01336686 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Oral Febuxostat in Participants With Gout
NCT00430248 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT04052932 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
NCT05119686 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
NCT02139046 ·Status: COMPLETED ·Phase: PHASE3
-
Combining Lesinurad With Allopurinol in Inadequate Responders
NCT01493531 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
NCT05253833 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
NCT02252835 ·Status: COMPLETED ·Phase: PHASE2
-
Combining Lesinurad With Allopurinol in Inadequate Responders
NCT01510158 ·Status: COMPLETED ·Phase: PHASE3
-
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
NCT04987294 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
NCT06439602 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
NCT03906006 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
NCT07089875 ·Status: RECRUITING ·Phase: PHASE3
-
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
NCT01416402 ·Status: COMPLETED ·Phase: PHASE2
-
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
NCT01508702 ·Status: COMPLETED ·Phase: PHASE3
-
The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
NCT03131583 ·Status: COMPLETED ·Phase: PHASE1
-
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT04956432 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
NCT00610363 ·Status: COMPLETED ·Phase: PHASE2
-
Does Allopurinol Prolong a Treated, Acute Gout Flare?
NCT01988402 ·Status: COMPLETED ·Phase: PHASE4
-
RDEA3170 and Allopurinol Combination Study in Gout Subjects
NCT02279641 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
NCT01510769 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
NCT04155918 ·Status: COMPLETED ·Phase: PHASE2